API
< Back to all clusters
[HEALTH] · 3 sources

started · updated

ALS research shows progress in clinical trials and referral efficacy

Recent developments in Amyotrophic lateral sclerosis (ALS) research highlight both clinical advancements and improvements in diagnostic referral processes. In a phase 2b PARADIGM study, Neurosense Therapeutics reported positive results for PrimeC, an experimental oral treatment. The randomized, double-blind, placebo-controlled trial involving 68 adults demonstrated that PrimeC significantly reduced levels of TDP-43, a protein that abnormally accumulates in 97% of ALS cases. The study also indicated a statistically significant slowing of functional decline, leading to plans for a global phase 3 clinical trial.

In a separate quality improvement project, an educational intervention using the thinkALS tool was implemented among primary care nurse practitioner students. The study found a statistically significant improvement in the students' self-reported self-efficacy to initiate referrals to specialized ALS multidisciplinary clinics. This intervention aims to address long-standing diagnostic delays by streamlining the referral process to specialized care centers.

Entities

Amyotrophic Lateral Sclerosis · Neurosense Therapeutics · PrimeC · Thomas Jefferson University